Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops
Source: Benzinga ·

Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based therapies support bone health during weight loss, while once-weekly semaglutide significantly reduces body mass index in children with obesity. Amylin Pipeline Pr
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.